Stock Rating Upgrade
The Value Trend Rating for Ligand Pharmaceuticals Inc (NASDAQ: LGND) improved recently from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
Ligand Pharmaceuticals Inc (NASDAQ: LGND) stock closed at $73.77 on 3/8/24 after an increase of 1.8%. Moreover, this advance was accompanied by above average trading volume at 134% of normal. Relative to the market the stock has been strong over the last nine months but has declined -7.0% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, LGND is expected to continue to be an important Value Builder.
Ligand Pharmaceuticals has a current Value Trend Rating of C (Neutral). This VT Rating improved in recent days from D previously. This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Ligand Pharmaceuticals has a poor Appreciation Score of 29 but a good Power Rating of 71, and the Neutral Value Trend Rating results.
Be the first to comment